Combination versus sequential single agent chemotherapy for metastatic breast cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Dear, Rachel F ^a   Mcgeechan, Kevin ^b   Jenkins, Marisa C ^b   Barratt, Alexandra ^b   Tattersall, Martin H N ^a   Wilcken, Nicholas ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LIOTHYRONINE; METHOTREXATE; PACLITAXEL; PREDNISONE; VINCRISTINE; VINORELBINE TARTRATE; XELODA X;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DISEASE COURSE; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; META ANALYSIS; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; MORTALITY; NAUSEA; PATHOLOGY; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NAUSEA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84897368219     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008792.pub2     Document Type: Review

References (38)

1. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. Journal of Clinical Oncology 2004;22(13):2587-93.
2. Baker LH, Vaughn CB, Al-Sarraf M, Reed ML, Vaitkevicius VK. Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 1974;33(2):513-8.
3. Beslija S, Obralic N, Basic H, Tatarevic M, Naila M, Banjin A, et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology 2006;24(18 Suppl):571.
4. Chlebowski RT, Smalley RV, Weiner JM, Irwin LE, Bartolucci AA, Bateman JR. Combination versus sequential single agent chemotherapy in advanced breast cancer: association with metastatic sites and long-term survival. British Journal of Cancer 1989;59(2):227-30.
5. Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. Cancer 2004;101(4):704-12.
6. Cresta S, Grasselli G, Mansutti A, Martoni A, Lelli G, Capri G, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Annals of Oncology 2004;15(3):433-9.
7. Fountzilas G, Papadimitriou C, Dafni U, Bafaloukos D, Skarlos D, Moulopoulos LA, et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology 2001;19(8):2232-9.
8. Koroleva I, Wojtukiewicz M, Zaluski J, Arzumanov A, Biakhov M, Gad-El-Mawla N, et al. Preliminary results of a phase II randomized trial of Taxotere (T) and doxorubicin (A) given in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). American Society of Clinical Oncology 2001;20:abstract 117.
9. Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Investigational New Drugs 2010;28(5):659-69.
10. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). Journal of Clinical Oncology 2003;21(4):588-92.
11. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 2006;24(18 Suppl):570.
12. Tomova A, Bartsch R, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C, et al. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Research and Treatment 2010;119(1):169-76.
13. Chlebowski RT, Irwin LE, Pugh RP, Sadoff L, Hestorff R, Wiener JM, et al. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Research 1979;39(11):4503-6.
14. Smalley RV, Murphy S, Huguley CM, Bartolucci AA. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Research 1976;36(11 Pt 1):3911-6.
15. Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie S, Mefti F, et al. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. The Breast Journal 2013;19(3):240-9.
16. Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, et al. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?. Cancer Chemotherapy and Pharmacology 2013;71(1):103-13.
17. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. JAMA 1995; Vol. 273, issue 7:542-7. [: 0098-7484]
18. Butters DJ, Ghersi D, Wilcken N, Kirk SJ, Mallon PT. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: ]
19. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, et al. International guidelines for managment of metastatic breast cancer: combination vs sequential single-agent chemotherapy. Journal of the National Cancer Institute 2009;101(17):1174-81.
20. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). The Breast 2012;21(3):242-52.
21. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: ]
22. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110(5):973-9.
23. Day RS. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Research 1986; Vol. 46, issue 8:3876-85.
24. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results -Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Cochrane Database of Systematic Reviews, UK: John Wiley & Sons, Ltd 2006, issue 2.
25. Farquhar C, Marjoribanks J, Basser R, Hetrick SE, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplant versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: ]
26. Ferlay JB, Bray FP, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004: http://www-dep.iarc.fr/ 2004.
27. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 2004;100(1):44-52.
28. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatment Reports 1982; Vol. 66, issue 3:439-49.
29. Hayes DF, Henderson IC, Shapiro CL, Hortobagyi GN, Abeloff MD. Treatment of metastatic breast cancer: Present and future prospects. Seminars in Oncology 1995;22 Suppl 5:5-21.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; Vol. 21(11):1539-58.
31. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews for Interventions. Chichester: John Wiley & Sons, 2011.
32. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Seminars in Oncology 1996; Vol. 23, issue 5 Suppl 11:1-5. [: 0093-7754]
33. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Seminars in Oncology 1987; Vol. 14, issue 4 Suppl 4:3-11. [: 0093-7754]
34. Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, et al. Prospective exploratory analysis of the association between tumour response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. Journal of Clinical Oncology 2002;20(17):3665-73.
35. Norton L, Day RS. Potential innovations in scheduling in cancer chemotherapy. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Philadelphia: Lippincott-Raven Publishers, 1991.
36. Shin DB, Bang SM, Park SH, Kang HG, Jue JI, Han SH. Correlation of quality of life with tumour response in patients receiving palliative chemotherapy for advanced gastrointestinal tumours. Medical Oncology 2008;25(1):81-7.
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92(3):205-16.
38. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 7 June 2007;8:16.